Literature DB >> 12716772

Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans.

Mohammad A Hossain1, Guadalupe H Reyes, Lisa A Long, Pranab K Mukherjee, Mahmoud A Ghannoum.   

Abstract

The activity of caspofungin (CFG) combined with amphotericin B (AMB) against azole-resistant Candida albicans was evaluated in vitro (chequerboard) and in vivo (murine). CFG+AMB resulted in positive interactive effects in vitro (fractional inhibitory concentration index 0.75). Compared with untreated controls, CFG+AMB prolonged mouse survival (P = 0.006) and compared with AMB alone, CFG+AMB prolonged mouse survival (P = 0.36); however, the latter difference was not significant. CFG+AMB treatment significantly reduced kidney cfu compared with untreated controls and CFG-treated groups (P < or = 0.05 for both comparisons). In addition, this combination reduced brain cfu significantly compared with untreated controls and AMB-treated mice (P = 0.005 and 0.05, respectively).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12716772     DOI： 10.1093/jac/dkg230

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

2.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 3.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Refractory candidal meningitis in an immunocompromised patient cured by caspofungin.

Authors:  Kung-Hung Liu; Chi-Jung Wu; Chen-Hsi Chou; Hsin-Chun Lee; Nan-Yao Lee; Shao-Tsung Hung; Wen-Chien Ko
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

Review 5.  Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

Authors:  Gillian Keating; David Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Effects of antifungal agents alone and in combination against Candida glabrata strains susceptible or resistant to fluconazole.

Authors:  Izabel Almeida Alves; Laíssa Arévalo Bandeira; Débora Alves Nunes Mario; Laura Bedin Denardi; Louise Vignoles Neves; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2012-04-22       Impact factor: 2.574

7.  Caspofungin in combination with amphotericin B against Candida parapsilosis.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Serena Tomassetti; Daniele Giannini; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

Review 8.  [Therapy of severe fungal infections].

Authors:  M Battegay; U Flückiger
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

9.  In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans.

Authors:  S Nishanth Kumar; Bala Nambisan; C Mohandas; A Sundaresan
Journal:  Folia Microbiol (Praha)       Date:  2013-02-28       Impact factor: 2.099

10.  Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.

Authors:  V Nagappan; D Boikov; J A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.